ClinicalTrials.gg
CompletedNCT02730663Updated Sep 17, 2019Results posted

A Study to Evaluate the Effectiveness and Safety of EUS-guided Transluminal Drainage With 'Niti-S SPAXUS Stent'

An interventional study of Niti-S SPAXUS Stent in Pancreatic Pseudocyst, sponsored by Taewoong Medical Co., Ltd.. Completed at 6 sites in Korea, Republic of. Open to participants aged 19 Years and older. Per ClinicalTrials.gov, last updated 2019-09-17.

Sponsored by Taewoong Medical Co., Ltd. (part of Olympus Corporation) · Not applicable, Interventional, and Treatment

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
36
Allocation
Not applicable
Ages
19 Years and older
Sex
All
01

Study summary

The purpose of this study is to evaluate the safety and effectiveness of endoscopic ultrasound (EUS)-guided transluminal drainage with 'Niti-S SPAXUS Stent' for the treatment of pancreatic pseudocyst.

Read the detailed description

'Niti-S SPAXUS Stent' is a newly designed lumen-apposing fully covered self-expandable metal stent. It is indicated for use in patients with pancreatic pseudocyst. Consecutive subject data should be collected at discharge, stent removal (day 30 or 60), and day 20 post Niti-S SPAXUS stent removal.

02

Conditions studied

  • Pancreatic Pseudocyst

Browse trials for

Keywords

  • Endoscopic ultrasound guided transluminal drainage
03

In context

Pancreatic Pseudocyst

32 studies on the registry are indexed under Pancreatic Pseudocyst; 10 are open to participants now.

This study's enrollment of 36 is below the median of 45 across 21 interventional studies indexed under Pancreatic Pseudocyst.

Browse Pancreatic Pseudocyst studies →

Lead sponsor

Taewoong Medical Co., Ltd. is the lead sponsor of 8 studies on the registry; 1 is open to participants now.

First submitted before Taewoong Medical Co., Ltd. became part of Olympus Corporation.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
19 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Pancreatic pseudocyst ≥6cm in size, with ≥70% fluid content that is eligible for transluminal drainage
  • Patient willing to provide written and comply with follow-up requirements

Exclusion criteria

Exclusion Criteria:

  • Ineligible for endoscopic intervention
  • Pancreatic pseudocyst with severe internal septation
  • count \< 60,000 cells/mm3 or (INR) >1.5
  • Hemodynamic instability (e.g. shock)
  • Active infectious disease (e.g. endocarditis, meningitis)
  • Participating in any other drug or device clinical trial within past 3 months
  • Female of who are unable to take adequate precautions, are known to be pregnant, or are currently breastfeeding an infant
Terms in these criteria, in plain language(6)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

INR, PT and aPTT (clotting tests)

Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.

Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
36 participants (actual)

Study arms

  • Experimental
    Niti-S SPAXUS Stent

    Niti-S SPAXUS Stent (TaeWoong Medical Co., Ltd. Korea)

    Device: Niti-S SPAXUS Stent

Interventions

  • DeviceNiti-S SPAXUS Stent

    Endoscopic Ultrasound-Guided Transluminal drainage

06

What researchers measure

Primary outcomes

  1. Number of Participants With Clinical Success

    Clinical success is defined as ≥50% decrease in pancreatic pseudocyst size measured on Computed Tomography (CT)

    Time frame: at stent removal (Day 30 or Day 60)

Secondary outcomes

  1. Number of Participants With Technical Success

    Technical success is defined as successful placement of the Niti-S SPAXUS stent across the gastric(or duodenal) wall to the pseudocyst with visualization of the pseudocyst fluid drainage through the stent by endoscopy.

    Time frame: Day 1

  2. Number of Participants With Stent Lumen Patency

    Stent lumen patency will be evaluated by endoscopy.

    Time frame: up to 60 days (at stent removal, Day 30 or 60)

  3. Number of Participants With Stent Removal Success

    Stent removal success is defined as successful removal of the Niti-S SPAXUS stent using a standard endoscopic forceps or snare.

    Time frame: up to 60 days (at stent removal, Day 30 or 60)

  4. Procedure Time

    Procedure time is measured as time from insertion until removal of endoscope. Procedure time 1: The time from the moment that the endoscope is inserted into the oral cavity to the time point at which the endoscope is removed. (sec) Procedure time 2: The time from the puncture time to the point at which the ultrasound endoscope was removed. (sec)

    Time frame: 1 day

  5. Number of Participants With Procedural/Device Related Serious Adverse Events

    The incidence of serious adverse events related to the procedure or the Niti-S SPAXUSTM stent is assessed at Day 20 after the stent removal

    Time frame: up to 90 days (at Day 20 post stent removal)

  6. Other Adverse Events

    The severity and incidence of all other adverse events than those mentioned above occurred during the follow-up period were evaluated at Day 20 day after the stent removal.

    Time frame: up to 90 days (at Day 20 post stent removal)

07

Results

Posted Jul 1, 2019

Participant flow

It took about 15 months from the approval of the Ministry of Food and Drug Safety(MFDS) and the IRB, including the subject enrollment period of about 13 months and the follow-up period of 2 months at maximum.

Participant flow — Overall Study
MilestoneNiti-S SPAXUS Stent
Started36
Completed35
Not completed1

Outcome measures

PrimaryNumber of Participants With Clinical Success

Clinical success is defined as ≥50% decrease in pancreatic pseudocyst size measured on Computed Tomography (CT)

Time frame:
at stent removal (Day 30 or Day 60)
Reported as:
Number · participants
Number of Participants With Clinical Success
participantsNiti-S SPAXUS Stent
Number of Participants With Clinical Success33
Statistical analysis
  • Niti-S SPAXUS Stent · t-test, 2 sided · p = 0.05 (A two-tail test was performed for statistics at a significance level of 0.05 unless otherwise specified.) · Reference value: -0.07
SecondaryNumber of Participants With Technical Success

Technical success is defined as successful placement of the Niti-S SPAXUS stent across the gastric(or duodenal) wall to the pseudocyst with visualization of the pseudocyst fluid drainage through the stent by endoscopy.

Time frame:
Day 1
Reported as:
Count of participants · Participants
Number of Participants With Technical Success
ParticipantsNiti-S SPAXUS Stent
Number of Participants With Technical Success33
SecondaryNumber of Participants With Stent Lumen Patency

Stent lumen patency will be evaluated by endoscopy.

Time frame:
up to 60 days (at stent removal, Day 30 or 60)
Reported as:
Count of participants · Participants
Number of Participants With Stent Lumen Patency
ParticipantsNiti-S SPAXUS Stent
Number of Participants With Stent Lumen Patency34
SecondaryNumber of Participants With Stent Removal Success

Stent removal success is defined as successful removal of the Niti-S SPAXUS stent using a standard endoscopic forceps or snare.

Time frame:
up to 60 days (at stent removal, Day 30 or 60)
Reported as:
Count of participants · Participants
Number of Participants With Stent Removal Success
ParticipantsNiti-S SPAXUS Stent
Number of Participants With Stent Removal Success34
SecondaryProcedure Time

Procedure time is measured as time from insertion until removal of endoscope. Procedure time 1: The time from the moment that the endoscope is inserted into the oral cavity to the time point at which the endoscope is removed. (sec) Procedure time 2: The time from the puncture time to the point at which the ultrasound endoscope was removed. (sec)

Time frame:
1 day
Reported as:
Mean · sec
Procedure Time
secNiti-S SPAXUS Stent
Procedure time 11074.88 ± 618.30
Procedure time 2618.12 ± 341.63
SecondaryNumber of Participants With Procedural/Device Related Serious Adverse Events

The incidence of serious adverse events related to the procedure or the Niti-S SPAXUSTM stent is assessed at Day 20 after the stent removal

Time frame:
up to 90 days (at Day 20 post stent removal)
Reported as:
Number · participants
Number of Participants With Procedural/Device Related Serious Adverse Events
participantsNiti-S SPAXUS Stent
Number of Participants With Procedural/Device Related Serious Adverse Events14
SecondaryOther Adverse Events

The severity and incidence of all other adverse events than those mentioned above occurred during the follow-up period were evaluated at Day 20 day after the stent removal.

Time frame:
up to 90 days (at Day 20 post stent removal)
Reported as:
Number · case
Other Adverse Events
caseNiti-S SPAXUS Stent
Other Adverse Events154

Adverse events

Collected over 3months. Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Niti-S SPAXUS Stent0/35 (0%)14/35 (40%)29/35 (82.9%)
Most frequent serious events
Most frequent serious events
EventNiti-S SPAXUS Stent
Infected pseudocystInfections and infestations3/35
Aggravated Walled off necrosisGastrointestinal disorders2/35
Abdominal painGastrointestinal disorders2/35
Necrotizing pseudocystGastrointestinal disorders2/35
Upper gastrointestinal bleedingGastrointestinal disorders1/35
DehydrationMetabolism and nutrition disorders1/35
Peripancreatic abscessInfections and infestations1/35
Pancreatic cancerNeoplasms benign, malignant and unspecified (incl cysts and polyps)1/35
Abdominal pain (LUQ pain) -> wall-off necrosisGastrointestinal disorders1/35
Cerebral infarctionNervous system disorders1/35
Most frequent other events
Showing 10 of 12
Most frequent other events
EventNiti-S SPAXUS Stent
Abdominal pain etc.Gastrointestinal disorders24/35
Pyrexia etc.General disorders17/35
Decreased appetiteMetabolism and nutrition disorders9/35
Pancreas infection etc.Infections and infestations7/35
Flank painMusculoskeletal and connective tissue disorders6/35
Blood pressure decreasedInvestigations5/35
Cholelithiasis etc.Hepatobiliary disorders2/35
ThrombocytosisBlood and lymphatic system disorders1/35
TachycardiaCardiac disorders1/35
Visual impairmentEye disorders1/35

Baseline characteristics

Age, Continuous
Age, Continuous(years)Niti-S SPAXUS Stent
Mean52.51 ± 13.22
Sex: Female, Male
Sex: Female, Male(Participants)Niti-S SPAXUS Stent
Female8
Male27
Race and Ethnicity Not Collected
Race and Ethnicity Not Collected(Participants)Niti-S SPAXUS Stent
Region of Enrollment
Region of Enrollment(participants)Niti-S SPAXUS Stent
South Korea35
Height
Height(cm)Niti-S SPAXUS Stent
Mean167.82 (144.30 to 182.30)
Body weight
Body weight(kg)Niti-S SPAXUS Stent
Mean64.34 (43.50 to 96.00)
History of smoking
History of smoking(participants)Niti-S SPAXUS Stent
Current Smoker13
Ex-Smoker10
Non-Smoker12
Alcohol drinking
Alcohol drinking(participants)Niti-S SPAXUS Stent
Current Drinker13
Ex-Drinker14
Non-Drinker8

1 further baseline measures are reported on the registry.

08

Study locations

6 sites
  • Soon Chun Hyang University Hospital Bucheon
    Bucheon, Gyeonggi-do 14584, Korea, Republic of
  • Hallym University Dongtan Sacred Heart Hospital
    Hwaseong-si, Gyeonggi-do 18450, Korea, Republic of
  • Kyungpook National University Medical Center
    Daegu, 41404, Korea, Republic of
  • Chonbook National University Hospital
    Jeonju, 54907, Korea, Republic of
  • Asan Medical Center
    Seoul, 05505, Korea, Republic of
  • Samsung Medical Center
    Seoul, 06351, Korea, Republic of
09

References and documents

Publications

  • Song TJ, Lee SS, Moon JH, Choi HJ, Cho CM, Lee KH, Park SW, Kim SH, Lee SO, Lee YN, Lee JK. Efficacy of a novel lumen-apposing metal stent for the treatment of symptomatic pancreatic pseudocysts (with video). Gastrointest Endosc. 2019 Sep;90(3):507-513. doi: 10.1016/j.gie.2019.05.033. Epub 2019 May 30. PubMed 31152738 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No — Oct, 2016

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Mar 2016 to primary completion in Jun 2017, 14 months.

Results were first posted in Jul 2019, 2 years after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 28, 2016
First posted
Apr 6, 2016
StartActual
Mar 21, 2016
Primary completionActual
Jun 14, 2017
CompletionActual
Jun 14, 2017
Results first posted
Jul 1, 2019
Last update
Sep 17, 2019
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 17, 2019, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT02730663
Responsible party
Sponsor
First posted
Apr 6, 2016
Start date
Mar 21, 2016
Primary completion
Jun 14, 2017
Completion
Jun 14, 2017
Results posted
Jul 1, 2019
Last update
Sep 17, 2019

Study contacts

Jong Ho Moon, PhD, MD
principal investigator · Soon Chun Hyang University
Sang Soo Lee, PhD, MD
principal investigator · Asan Medical Center
Jong Kyun Lee, PhD, MD
principal investigator · Samsung Medical Center
Seung-Ok Lee, PhD, MD
principal investigator · Chonbuk National University Hospital
Chang Min Cho, PhD, MD
principal investigator · Kyungpook National University Medical Center
Se Woo Park, PhD, MD
principal investigator · Hallym University Dongtan Sacred Heart Hospital

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Apr 2019. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion